

## OPKO Health (USA): Acquisition of Bio-Reference Laboratories (USA) Changes in FTSE RAFI™ Index Series

20 August 2015

Following the completion of the acquisition of Bio-Reference Laboratories by OPKO Health (USA, constituent), FTSE announces the following changes:

Index	Change	Effective From Start of Trading
FTSE RAFI US 1500 Mid Small Index	Bio-Reference Laboratories (USA, 2575551) will be deleted from the index.  OPKO Health (USA, 2115902) will remain in the index.	25 August 2015
FTSE RAFI US 1500 Mid Small Index - QSR	Bio-Reference Laboratories will be deleted from the index.  OPKO Health will remain in the index.	25 August 2015

For further information or general enquiries please contact us at [info@ftse.com](mailto:info@ftse.com) or call:

Client Services in UK:	Tel: +44 (0) 20 7866 1810
Client Services in EMEA:	Tel: +44 (0) 20 7866 1810
Client Services in US:	New York: (Domestic) + 1 888 747 FTSE (3873) / (International): +1 212 314 1139
Client Services in Asia Pacific:	Hong Kong: + 852 2164 3333 Australia:(Domestic Toll-Free) + 1800 653 680 / (International) + 61 (2) 9293 2864 Japan + 81 (3) 3581 2764

Alternatively please visit our website at [www.ftse.com](http://www.ftse.com)

[Terms of Use](#) | Copyright © FTSE